Eli Lilly and Company has become a key player in the production of tirzepatide, a groundbreaking medication for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, showcases significant potential to improve glycemic control and reduce the risk of cardiovascular disease. The complex manufacturing process of tirzepatide requires a se